Description
Adakveo (crizanlizumab) is a prescription medication used to reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease. The medication is administered by intravenous injection.
Uses:
Adakveo is used to reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease. VOCs occur when sickle-shaped red blood cells block small blood vessels, leading to severe pain and organ damage. Adakveo works by binding to a molecule called P-selectin, which is involved in the adhesion of sickle cells to blood vessel walls.
Storage Conditions:
Adakveo should be stored in its original packaging at a temperature between 2°C and 8°C. The medication should not be frozen or shaken. Once prepared, the medication should be used immediately or stored in a refrigerator for up to 24 hours.
Mechanism of Action:
Adakveo is a monoclonal antibody that binds to P-selectin, a molecule found on the surface of certain cells involved in inflammation. P-selectin facilitates the adhesion of sickle cells to blood vessel walls, which leads to VOCs. By blocking P-selectin, Adakveo helps to reduce the incidence of VOCs in patients with sickle cell disease.
HOW TO USE:
Adakveo is administered by intravenous injection. The recommended dosage is 5 mg/kg body weight, given every four weeks. The medication should be administered by a healthcare professional trained in intravenous administration, and patients should be monitored for adverse reactions.
Precautions:
• Patients with a history of hypersensitivity or anaphylaxis to Adakveo or any of its components should not receive the medication.
• Adakveo should be used with caution in patients with a history of thrombosis or concurrent use of other medications that increase the risk of bleeding.
• Patients should inform their healthcare provider of any other medical conditions they have, any medications they are taking, or if they are pregnant, planning to become pregnant, or breastfeeding.
Drug Interactions:
Adakveo may interact with other medications, including anticoagulants and antiplatelet drugs, which increase the risk of bleeding. Patients should inform their healthcare provider of all medications, supplements, or herbal products they are taking before starting treatment with Adakveo.
Contraindications:
• Adakveo is contraindicated in patients with a history of hypersensitivity or anaphylaxis to Adakveo or any of its components.
• Adakveo should not be used during pregnancy or breastfeeding.
Overdose:
There is no specific treatment for Adakveo overdose; patients who have received an overdose should be monitored for adverse reactions.
Adverse Reactions:
The most common adverse reactions reported with the use of Adakveo include nausea, fever, rash, and back pain. Other adverse reactions reported include infections, infusion reactions, and hypersensitivity reactions. Patients should inform their healthcare provider of any unusual or unexpected reactions while using Adakveo.
In conclusion, Adakveo (crizanlizumab) is a medication used to reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease. The medication is administered by intravenous injection and works by binding to P-selectin, a molecule involved in the adhesion of sickle cells to blood vessel walls. Adakveo should be stored in its original packaging in the refrigerator and used immediately once prepared or within 24 hours. Patients with a history of hypersensitivity or anaphylaxis to Adakveo or any of its components should not receive the medication. Adakveo should not be used during pregnancy or breastfeeding. Patients taking other medications before treatment should inform their healthcare provider, and the most common adverse reactions reported include nausea, fever, rash, and back pain. In case of an overdose, patients should be monitored for adverse reactions.
Reviews
There are no reviews yet.